Investment to Help Take Market Entry Forward

Stephanie Brooking has joined gene synthesis solutions provider Evonetix as Head of Product Management to take the company forward with its marketing strategy plans. The company aims to utilise its silicon chip technology to deliver a high-throughput solution for the synthesis and assembly of DNA molecules with high fidelity. Stephanie will help to define the company’s strategy for market entry and longer-term product marketing for its novel gene synthesis products.

Stephanie has over 20 years’ commercial experience in the life science industry, having worked in operational, sales and marketing leadership roles. She has helped execute programmes to open new geographies and market opportunities within research, clinical, agricultural, pharmaceutical and biotechnology sectors. Previously she was the VP of Marketing and Sales at Cambridge Epigenetix, Global Commercial Director at Oxford Nanopore Technologies and has also held senior positions at Illumina, Applied Biosystems, Affymetrix and GE Healthcare (Amersham Pharmacia Biotech). She first began her career working on the Human Genome Project at the Wellcome Trust Sanger Institute.

Dr Tim Brears, Evonetix CEO, said: “Following last year’s fundraising we have been investing in key roles and we are delighted to have Stephanie join our team. She brings a wealth of commercial experience and invaluable expertise in leading product development and marketing strategies, which will be a great asset to Evonetix as we continue to progress with developing our gene synthesis platform.”